Pathophysiology of ascites and dilutional hyponatremia: Contemporary use of aquaretic agents

Annals of Hepatology

Volumn 6, Issue 4, 2007, Pages 214-221

  Leiva, Jorge García ^a   Salgado, Julio Martínez ^a   Estradas, Jose ^a   Torre, Aldo ^a   Uribe, Misael ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Aquaretics; Ascites; Dilutional hyponatremia pathophysiology

Indexed keywords

ALDOSTERONE; AMILORIDE; ANGIOTENSIN; AQUAPORIN; AQUAPORIN 1; AQUAPORIN 2; AQUAPORIN 3; AQUAPORIN 4; AQUAPORIN 5; ATRIAL NATRIURETIC FACTOR; CALCITONIN GENE RELATED PEPTIDE; CONIVAPTAN; DIURETIC AGENT; FUROSEMIDE; LIXIVAPTAN; LOOP DIURETIC AGENT; MOZAVAPTAN; NIRAVOLINE; OPIATE; RELCOVAPTAN; RENIN; SATAVAPTAN; SODIUM; SPIRONOLACTONE; TOLVAPTAN; UNINDEXED DRUG; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ASCITES; CONFUSION; DIURETIC THERAPY; HEART OUTPUT; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTENSION; KIDNEY FUNCTION; LIVER CIRRHOSIS; MONOTHERAPY; NONHUMAN; PARACENTESIS; PATHOPHYSIOLOGY; PERSONALITY DISORDER; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SODIUM RESTRICTION; SODIUM RETENTION; TACHYCARDIA; VASCULAR RESISTANCE; VASODILATATION; WATER DEPRIVATION; WATER RETENTION;

AQUAPORINS; ASCITES; DIURETICS; FUROSEMIDE; HUMANS; HYPONATREMIA; LIVER CIRRHOSIS; RECEPTORS, VASOPRESSIN; SODIUM; SPIRONOLACTONE; VASOPRESSINS; WATER-ELECTROLYTE BALANCE;

EID: 37549018061     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Runyon BA. Care of patients with ascites. N Engl J Med 1994; 330: 337-342.
2. Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004; 39: 841-854.
3. Gines P, Beri T, Bernardi M, Bichet DG, Hamon G, Jimenez W, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998; 28: 851-861.
4. Arroyo V. Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Ann Hepatol 2002; 2: 72-79.
5. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiology basis of therapy and current management. J Hepatol 2003; 38: S69-S89.
6. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-1654.
7. Lieberman FL, Ito S, Reynolds TB. Effective plasma volume in cirrhosis with ascites. Evidence that a decreased value does not account for renal sodium retention, a sponteneous reduction in glomerular filtration rate (GFR), and a fall in GFR during drug-induced diuresis. J Clin Invest 1969; 48: 975-81.
8. Gentilini P, Laffi G, La Villa G, Romanelli RG, Blendis LM. Ascites and hepatorenal syndrome in cirrhosis: two entities or the continuation of the same complication? J Hepatol 1999; 31: 1088-1097.
9. Henriksen JH. Ascites and hepatorenal syndrome: recent advances in pathogenesis. J Hepatol 1995; 23(Supp 1): 25-30.
10. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8(5): 1151-7.
11. Peña JC. Mecanismos renales y extrarenales en la retención de sodio y agua en la cirrosis con ascitis. Rev Invest Clin 1995; 47: 63-79.
12. Rivera A, Peña JC, Barcena C, Rangel S, Dies F. Renal excretion of water, sodium and potassium in cirrhosis of the liver. Metabolism 1961; 10: 1-17.
13. Henriksen JH. Ascites and hepatorenal syndrome: recent advances in pathogenesis. J Hepatol 1995; 23(Supp 1): 25-30.
14. Aiza I, Perez GO, Schiff ER. Management of ascites in patients with chronic liver disease. Am J Gastroenterol 1994; 89: 1949-1955.
15. Arroyo V, Gines P. Mechanism of sodium retention and ascites formation in cirrhosis. J Hepatol 1993; 17(suppl 2): S24-S28.
16. Arroyo V, Claria J, Salo J. Antidiuretic hormona and the pathogenesis of water retention in cirrosis with ascites. Sem Liver Dis 1994; 14: 44-58.
17. Boyer TD. Aquaretics in cirrhotics with hyponatremia. J Gastroenterol Hepatol 2004; 19: S191-S193.
18. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the international ascites club. Hepatology 2003; 38: 258-266.
19. Brater DC. Diuretic therapy. N Engl J Med 1998; 339: 387-395.
20. Gines P, Arroyo V. Paracentesis in the management of cirrhotic ascites. J Hepatol 1993; 17(suppl 2): S14-S18.
21. Arroyo V. Albumin in the treatment of liver disease - new features of a classical treatment. Aliment Pharmacol Ther 2002; 16 (suppl 5): 1-5.
22. Torre Delgadillo A. Ascitis refractaria e hiponatremia dilucional: tratamiento actual y nuevos acuaréticos: Rev Gastroenterol Mex. 2005; 70(3): 299-311.
23. Nejsum LN. The renal plumbing system: aquaporin water channels. Cell Mol Life Sci 2005; 62: 1692-1706.
24. Preston GM, Carroll TP, Guggino WB, Agre P. Appearance of water channels in Xenopus oocytes expressing red cell CHIP28 protein. Science 1992; 256: 385-387.
25. Nejsum LN. The renal plumbing system: aquaporin water channels. Cell Mol Life Sci 2005; 62: 1692-1706.
26. Fernandez-Llama P, Turner R, Dibona G, Knepper MA. Renal expression of aquaporins in liver cirrhosis induced by chronic common bile duct ligation in rats. J Am Soc Nephrol 1999; 10: 1950-7.
27. Fernandez-Llama P, Jimenez W, Bosch-Marce M, Arroyo V, Nielsen S, Knepper MA. Dysregulation of renal aquaporins and Na-Cl cotransporter in CCl4-induced cirrhosis. Kidney Int 2000; 58: 216-28.
28. Tajika Y, Matsuzaki T, Suzuki T, Aoki T, Hagiwara H, Kuwahara M, et al. Aquaporin-2 is retrieved to the apical storage compartment via early endosomes and phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2004; 145: 4375-4383.
29. Yamamoto T, Sasaki S, Fushimi K, Kawasaki K, Yaoita E, Oota K, et al. Localization and expression of a collecting duct water channel, aquaporin, in hydrated and dehydrated rats. J Exp Nephrol 1995; 3: 193-201.
30. Gines P, Jimenez W. Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis. J Hepatol 1996; 24: 506-512.
31. Gadano A, Moreau R, Pessione F, Trombino C, Giuily N, Sinnassamy P, Valla D, Lebrec D. Aquaretic effects of niravoline, a k-opioid agonist, in patients with cirrhosis. Journal of Hepatology 2000; 32: 3842.
32. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417-2423.
33. Thibonnier M, Kilani A, Rahman M, et al. Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension 1999: 34: 1293-1300.
34. Ferguson JW, Therapondos G, Newby DE, Hayes PC. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clin Sci (Lond) 2003; 105: 1-8.
35. Chan PS, Coupet J, Park HC, Lai F, Hartupee D, Cervoni P, Dusza JP, et al. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol 1998; 449: 439-443.
36. Wong F, Blei, AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37: 182-191.
37. Inoue T, Ohnishi A, Matsuo A, Kawai B, Kunihiro N, Tada Y, Koizumi F, Chau T, Okada K, Yamamura Y, Tanaka T. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998; 63: 561-70.
38. Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002; 36: 1197-1205.
39. Patat A, Ellis-Grosse EJ, Orczyk GP, Gandon JM. Pharmacodynamic effects of a novel, non-peptide, V2 receptor antagonist, VPA-985, given with hydrochlorothiazide. Clin Pharmacol Ther 2000; 67: 110.
40. Swan SK, Lambvrecht LJ, Orczyk GP, Ellis-Grosse EJ. Interaction between VPA-985, an ADH (V2) antagonist, and furosemide. J Am Soc Nephrol 1999; 10: 124A.
41. Afdhal N, Andres Cardenas A, Gines P, Gross P, Verbalis J, Berl T, Schrier R, Bichet D, Wagoner L, Ouyang J. Randomized, placebo-controlled trial of tolvaptan, a novel v2-receptor antagonist, in hyponatremia: results of the salt 2 trial with emphasis on efficacy and safety in cirrhosis. Hepatology 2005; 42(S1): 756A.